Genentech doubles down on its PhIII Alzheimer’s campaign for crenezumab
Roche’s big biotech group Genentech is doubling down on one of the most prominent drugs in late-stage development for Alzheimer’s. The company is launching a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
